{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-24-000028","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.750744+00:00","generated_at":"2026-06-05T20:47:27.089506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Maravai Q4 revenue plunges 64% to $74.1M; net loss $110M; FY24 guidance $265-285M","bullets":["Revenue $74.1M (down 64% YoY); net loss $110M vs net income $87.4M year ago.","Nucleic Acid Production revenue $58.8M in Q4, down 69% YoY; COVID CleanCap revenue fell $105M YoY.","Full year 2023 revenue $288.9M (down 67% YoY); net loss $138.4M vs net income $490.7M.","Introduced 2024 revenue guidance of $265M-$285M, below 2023 actual.","Announced CleanCap patent awards in China/Canada, supply deal with FUJIFILM Toyama Chemical, and Cygnus-Dyadic partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-24-000028","json":"https://secwatch.observer/filing/0001823239-24-000028.json","markdown":"https://secwatch.observer/filing/0001823239-24-000028.md","text":"https://secwatch.observer/filing/0001823239-24-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/mrvi-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T20:47:27.089506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"339dc18123f28ea6aebfff43a2811df14ebaec5e","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported Fourth Quarter 2023 results: revenue Quarterly revenue of $74.1 million, net income Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets.","evidence_excerpt":"Quarterly revenue of $74.1 million, Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets, and Adjusted EBITDA margin of 28%;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2023"},{"label":"Revenue","value":"Quarterly revenue of $74.1 million"},{"label":"Net income","value":"Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"36277cf4ccdf8dc199f90c4ac150d8fba4640e98","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported financial results for for the fourth quarter ended December 31, 2023.","evidence_excerpt":"On February 22, 2024, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the fourth quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the fourth quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d4aa483b2c2cc47efc9bf5892da5be05410f7f1b","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported Full Year 2024 results: revenue $265.0 million to $285.0 million. Guidance initiated.","evidence_excerpt":"Introduced full year 2024 revenue guidance range of $265.0 million to $285.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2024"},{"label":"Revenue","value":"$265.0 million to $285.0 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e43d1b1e89edf7f64ece78ecd81bcc9e142ba02c","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported Full Year 2023 results: revenue Annual revenue of $288.9 million, net income Net loss of $(138.4) million.","evidence_excerpt":"Annual revenue of $288.9 million, Net loss of $(138.4) million, and Adjusted EBITDA margin of 23%;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"Annual revenue of $288.9 million"},{"label":"Net income","value":"Net loss of $(138.4) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}